

Some reading.....

1. NAD Deficiency, Congenital Malformations and Niacin Supplementation.

Shi H, Enriquez A, Rapadas M, Martin EMMA. Wang R, Moreau J, Lim CK, Szot JO, Ip E, Hughes J, Sugimoto K, Humphreys D, McInerney-Leo AM, Leo PJ, Maghzal GJ, Halliday J, Smith J, Colley A, Mark PR, Collins F, Sillence DO, Winlaw DS, Ho J, Guillemin GJ, Brown MA, Kikuchi K, Thomas PQ, Stocker R, Giannoulatou E, Chapman G, Duncan EL, Sparrow DB, **Dunwoodie SL.**

The New England Journal of Medicine. 2017;377(6):544-552.

2. Metabolism and Congenital Malformations — NAD's Effects on Development

Matthew G. Vander Heiden,

The New England Journal of Medicine. 2017; 377(6):509-511

Sally Dunwoodie

s.dunwoodie@victorchang.edu.au

Summer Student Scholarships



Victor Chang
Cardiac Research Institute

Identifying genetic and environmental factors that disrupt embryogenesis

Sally L Dunwoodie

s.dunwoodie@victorchang.edu.au



Dr Victor Chang AC 1936-1991, Pioneering Cardiothoracic Surgeon and Humanitarian

Mesoderm Development Lecture

Gastrulation

Early Mesoderm Development

Notochord

Paraxial Mesoderm


Intermediate Mesoderm

Lateral Plate Mesoderm

Early Heart Development


Dr Annemiek Beverdam – School of Medical Sciences, UNSW
Wallace Wurth Building Room 234 – A.Beverdam@unsw.edu.au

Somites give rise to the vertebral column



Notch
FGF
Wnt
Retinoic acid


bone
muscle
ligament
tendon



2: Paraxial Mesoderm

AP patterning


Somite Derivative Specification depends on AP level/*Hox* code



NOTCH1 target gene expression in the presomitic mesoderm



Lfng-GFP

Aulehla et al Nat Cell Biol 2008




Hes7-Luc



Kageyama et al WIREs Dev Biol 2012




NOTCH1 activity in the presomitic mesoderm



Dll3 is required for formation of somites and vertebrae



Genes required for somitogenesis in mouse




<i>Adam10</i>	<i>Efnb2</i>	<i>Meox1</i>	<i>Ripply1</i>
<i>Aldh1a2</i>	<i>Epha1</i>	<i>Meox2</i>	<i>Ripply2</i>
<i>Aphla</i>	<i>Fn1</i>	<i>Mesp2</i>	<i>Sfrp1</i>
<i>Axin1</i>	<i>Fgf3</i>	<i>Mib1</i>	<i>Sfrp2</i>
<i>Cdh2</i>	<i>Fgf4/Fgf8</i>	<i>Msgn1</i>	<i>Sip1</i>
<i>Cdh2</i>	<i>Fgfr1</i>	<i>Ncstn</i>	<i>Tbx6</i>
<i>Cdh11</i>	<i>Foxc1</i>	<i>Notch1</i>	<i>Tbx18</i>
<i>Cyp26a1</i>	<i>Foxc2</i>	<i>Pax1</i>	<i>Tcf15</i>
<i>Dact1</i>	<i>Has2</i>	<i>Pax3</i>	<i>Uncx</i>
<i>Dll1</i>	<i>Hes7</i>	<i>Pofut1</i>	<i>Wnt3a</i>
<i>Dll3</i>	<i>Itgav</i>	<i>Psen1</i>	<i>Zic2</i>
<i>Dkk1</i>	<i>Lef1</i>	<i>Rbpj</i>	<i>Zic3</i>
<i>Dvl2</i>	<i>Lfng</i>	<i>Rere</i>	
	<i>Lrp6</i>		



MOUSE

1-3 hours per somite
embryonic days 8-13
36 vertebrae + 26 in tail



HUMAN

4-6 hours per somite
embryonic days 20-30
33 vertebrae

Spondylocostal dysostosis (SCD) is caused by mutation in Notch associated genes

SCD1 *DLL3*



Bulman *et al* 2000
Turnpenny *et al* 2003

SCD2 *MESP2*



Whittock *et al* 2004

SCD3 *LFNG*



Sparrow *et al* 2006

SCD4 *HES7*



Sparrow *et al* 2008

SCD5 *TBX6*
dominant




Sparrow *et al* 2013

SCD6 *RIPPLY2*



McInerney-Leo *et al* 2014




Complex birth defects

heart
vertebra
kidney

limb
digit
palate


Folic acid supplementation reduces the incidence of neural tube defects



HAAO or KYNU variants in families with multiple congenital malformation and miscarriage


2005 – 2012

HAAO: p.D162 (HAAO)*




2015

HAAO: p.W186 (HAAO)*




2008 - 2014

*KYNU: p.V57Efs*21 (KYNU)*




2016

KYNU: p.Y156 (KYNU)
KYNU: p.F349Kfs*4 (KYNU)*




HAAO or *KYNU* variants in families with multiple congenital malformation and miscarriage



Patient	A HAAO	B HAAO	C KYNU	D KYNU
Vertebral segmentation anomalies	+		heart vertebra kidney	+
Cardiac	ASD			HLH
Renal	hypoplasia			solitary kidney, chronic disease
Limb	talipes		limb digit palate	short long bones
Ear	SNHL,			-
Other features	short stature, laryngeal malacia, ...,			short stature, speech delay

KYNU and HAAO required to synthesise NAD from tryptophan



Kynureninase

3-Hydroxyanthranilate 3,4-dioxygenase

NAD precursors

tryptophan 60:1

vitamin B3 1:1

niacin equivalents

Vitamin B3

niacin/nicotinic acid

nicotinamide

nicotinamide riboside

Building evidence of a gene or variant's role in disease

Does the variant disrupt protein function?

Does the variant affect protein function in patients?

Is the genes required for embryogenesis?



What alters penetrance and expressivity of the variant?

Are the variant enzymes active?

YES!

- quantifying enzymatic activity *in vitro*


Family	A	B	C	D
Gene	<i>HAAO</i>	<i>HAAO</i>	<i>KYNU</i>	<i>KYNU</i>
DNA variant(s)	c.483dupT homozygous	c.558G>A homozygous	c.170-1G>T homozygous	c.468T>A c.1045_1051 delTTAAGC
Protein variant(s)	p.D162*	p.W186*	p.V57Efs*21	p.Y156* p.F349Kfs*4



KYNU p.T198A that is associated with hydroxy-kynureninuria but not congenital malformation

Do the variants affect enzyme function in patients? YES!


-quantifying metabolites in patients




Is the genes required for embryogenesis?

YES

-identifying a phenotype in mice




Defects: heart, vertebral, kidney, cleft palate, talipes, syndactyly, caudal agenesis




Increase in upstream metabolites
Decrease in downstream metabolites

What alters the effect of (penetrance/expressivity) of the variant?


Niacin supplementation prevents NAD deficiency and defects




Niacin supplementation prevents NAD deficiency and defects




Niacin supplementation prevents NAD deficiency and defects




**Loss of *KYNU* or *HAAO* causes NAD deficiency and defects
humans and mice**



**Vitamin B3 supplementation bypasses mutations prevents NAD deficiency and defects
mice**



**Can diet cause NAD deficiency?
mice**




Methodologies used in this research


- genome sequencing (human)
- enzyme activity assays (*in vitro*)
- quantifying metabolites with LC-MS (human and mouse)
- generation of mutant mice (CRISPR-Cas9)
- mouse phenotyping (skeletal, heart, kidney, etc)
- whole mouse embryo phenotyping (microCT)

Using microCT to phenotype mouse embryos and whole litters


E11.5



E14.5



Gavin Chapman



s.dunwoodie@victorchang.edu.au



Dunwoodie Laboratory

Gavin Chapman

Justin Szot

Ella Martin

Joelene Major

Kavitha Iyer

Annabelle Enriquez

Dimuthu Alankarage

Hartmut Cuny

Jess Gereis

Debjani Das

Moran Almog

Duncan Sparrow

Hongjun Shi

Rosemary Kirk

Melissa Rapadas

Collaborators- clinical

David Sillence, Children's Hospital Westmead, Sydney

Janine Smith, Children's Hospital Westmead, Sydney

Alison Colley, Liverpool Hospital, Sydney

Paul Mark, Spectrum Health, Grand Rapids, Michigan

CHD Collaborators- clinical

David Winlaw, Children's Hospital Westmead, Sydney

Gillian Blue, Children's Hospital Westmead, Sydney

Nicholas Pachter, Genetic Services of WA, Perth

Katrina Harrison, Genetic Services of WA, Perth

Edwin Kirk, Sydney Children's Hospital, Sydney

Bioinformatics @ VCCRI

Eleni Giannoulatou

David Humphreys

Eddie Ip

Michael Troup



Australian Government

National Health and Medical Research Council



CHAIN REACTION
THE ULTIMATE CORPORATE BIKE CHALLENGE